HCW Biologics Says Q1 2026 Financial Statements Should No Longer Be Relied Upon; Error In Two-Class Method For EPS Calculation Identified; Errors Constitute Material Misstatement Of EPS; EPS Of $2.19 Per Share Overstated By $0.80 Per Share For Q1 2026; Material Weakness In Technical Accounting Review Control Identified

HCW Biologics, Partners Identify TGF-β Trap, IL-15 Fusion As Novel Moiety With Potential Applications Against Diseased Cell, Viral Infections

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 70.3% to $9.28 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million. The company's, Q2 earnings came

HCW Biologics Restates Q1 2026 EPS $1.39, Sales $6.543M Up From $5.065K YoY

8-K filing — HCW Biologics Inc. (HCWB)

Filed: 2026-08-14 AccNo: 0001493152-26-038258 Size: 323 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits